Cell Source Ltd.

www.cell-source.com

High-Tech Company
Public Company

(OTCQB: CLCS)

TECH VERTICALS

Biotechnology, Blood, Cancer, Immunology, Implants, Life Sciences, MedTech, Therapeutics, Treatment

General Data

Sector	Biomed
Company Stage:	R&D
Established	2011
Number of Employees	1
Reg. Number:	abCDe

DESCRIPTION

Cell Source is a biotechnology company focused on developing cell therapy treatments based on the management of immune tolerance. The company’s patented "Veto-Cell" technology represents a major breakthrough in immune system management - safe and selective “tolerizing” of immune response. This technology addresses one of the most fundamental challenges in human immunology: how to tune immune response so that it tolerates specific “desirable” foreign cells while continuing to attack all other potential threats.

Their mission is to revolutionize the fields of transplantation, cancer treatment and reversal of vital organ disease, utilizing their breakthrough immune tolerance and organ regeneration technologies, in order to save lives and fulfill the inspiring promise of immunotherapy.

TECHNOLOGY

The company’s patented "Veto-Cell" technology represents a major breakthrough in immune system management - safe and selective “tolerizing” of immune response.

Cell Source’s technology addresses one of the most fundamental challenges in human immunology: how to tune immune response so that it tolerates specific “desirable” foreign cells while continuing to attack all other potential threats.

The proprietary Anti 3rd Party Central Memory T cell (Tcm) is a next generation cell therapy treatment targeting specific patient immune system characteristics.

This technology was invented by Professor Yair Reisner and his team at the internationally recognized Weitzman Institute of Science in Rehovot, one of Israel’s leading scientific research centers. The core technology has already been granted patents, with patents pending for the latest developments.

Products and Phases

Product	Phase
Veto-Cell	Phase III
The company’s patented "Veto-Cell" technology represents a major breakthrough in immune system management - safe and selective “tolerizing” of immune response. Cell Source’s technology addresses one of the most fundamental challenges in human immunology: how to tune immune response so that it tolerates specific “desirable” foreign cells while continuing to attack all other potential threats. Cell Source is currently commercializing this groundbreaking innovation. Potential applications range from facilitating bone marrow and organ transplantation to effectively treating both blood cancers (e.g., Lymphoma) and non-malignant congenital diseases (e.g., Sickle Cell Anemia).

	TARGET MARKETS
	Patients Suffering From Various Immune Disorders in Need of Cell Therapy Treatment.

	BUSINESS MODEL
	B2C

CONTACT INFO

Expand / Collapse All

Main Address: New York, United States

Address	57 West 57th Street Suite 400
City	New York
State/Province	NY
Country	United States
Zip	10019

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Mr. Itamar Shimrat	CEO	Step Up (Director)
Mr. Yoram Drucker	Co-Founder	IR-MED (VP, Business Development & Chairman)

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Board Member	CEO, Cell Source
abC Defghij	Chairman of Scientific Advisory Board	Chairman of Immunology Department, Weizmann Institute
abC Defghij	Scientific Advisor	Director of the Medical Clinic at University of Würzburg, Germany

Public Offerings

Deal Date	Type of Offering	Exchange	Amount Raise	Valuation	Remarks
Jul. 02, 2014	Listing	OTCQB	abCDe	abCDe

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

PIPE

Jul. 02, 2014

R&D

abCDe

Seed

Dec. 21, 2013

Seed

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij*	Technology Transfer Company	abCDe
abC Defghij	Private Investor	abCDe

Last Updated:	abCDe
IVC Number:	abCDe